PURA VIDA INVESTMENTS, LLC - Q2 2018 holdings

Add to watchlist

$250 Million is the total value of PURA VIDA INVESTMENTS, LLC's 92 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 63.2% .

All

			Value		Shares		↓ Weighting
ICUI	Sell	ICU MED INC	$7,048,000	-0.3%	24,000	-14.3%	2.82%	-32.3%
LIVN	Sell	LIVANOVA PLC	$6,992,000	+9.6%	70,050	-2.8%	2.80%	-25.7%
XLV	Sell	SELECT SECTOR SPDR TRput	$5,008,000	-61.5%	60,000	-62.5%	2.01%	-73.9%
SIEN	Sell	SIENTRA INC	$3,588,000	+26.2%	183,900	-37.5%	1.44%	-14.4%
GMED	Sell	GLOBUS MED INCcl a	$3,406,000	-49.4%	67,500	-50.0%	1.36%	-65.6%
ATHN	Sell	ATHENAHEALTH INC	$3,342,000	-6.5%	21,000	-16.0%	1.34%	-36.6%
BAX	Sell	BAXTER INTL INC	$2,954,000	-39.4%	40,000	-46.7%	1.18%	-58.9%
XENT	Sell	INTERSECT ENT INC	$2,715,000	-37.2%	72,500	-34.1%	1.09%	-57.4%
SIEN	Sell	SIENTRA INCcall	$2,447,000	-49.7%	125,400	-75.1%	0.98%	-65.9%
DXCM	Sell	DEXCOM INC	$2,375,000	-13.8%	25,000	-32.7%	0.95%	-41.5%
IVC	Sell	INVACARE CORP	$2,283,000	-52.6%	122,735	-55.7%	0.92%	-67.8%
ZGNX	Sell	ZOGENIX INC	$2,001,000	-0.6%	45,268	-9.9%	0.80%	-32.5%
MRK	Sell	MERCK & CO. INC	$1,821,000	-66.6%	30,000	-70.0%	0.73%	-77.3%
RIGL	Sell	RIGEL PHARMACEUTICALS INC	$1,557,000	-24.7%	550,000	-5.9%	0.62%	-48.9%
NVTRQ	Sell	NUVECTRA CORP	$1,334,000	-8.9%	65,000	-42.2%	0.54%	-38.2%
ALXN	Sell	ALEXION PHARMACEUTICALS INC	$1,242,000	-75.2%	10,000	-77.8%	0.50%	-83.2%
RCKT	Sell	ROCKET PHARMACEUTICALS INC	$1,010,000	-24.6%	51,459	-28.0%	0.40%	-48.9%
BSX	Sell	BOSTON SCIENTIFIC CORP	$818,000	-65.8%	25,000	-71.4%	0.33%	-76.8%
INCY	Sell	INCYTE CORPcall	$670,000	-59.8%	10,000	-50.0%	0.27%	-72.7%
VKTX	Sell	VIKING THERAPEUTICS INC	$447,000	-41.5%	47,100	-73.1%	0.18%	-60.3%
OTIC	Sell	OTONOMY INC	$319,000	-50.2%	82,794	-45.7%	0.13%	-66.1%
VBLT	Exit	VASCULAR BIOGENICS LTDput	$0	–	-100,000	-100.0%	-0.14%	–
KALA	Exit	KALA PHARMACEUTICALS INCput	$0	–	-15,000	-100.0%	-0.14%	–
ARAY	Exit	ACCURAY INC	$0	–	-88,958	-100.0%	-0.26%	–
JNCE	Exit	JOUNCE THERAPEUTICS INC	$0	–	-21,700	-100.0%	-0.29%	–
BHVN	Exit	BIOHAVEN PHARMACTL HLDG CO Lput	$0	–	-20,000	-100.0%	-0.30%	–
CHRS	Exit	COHERUS BIOSCIENCES INCcall	$0	–	-50,000	-100.0%	-0.33%	–
GWPH	Exit	GW PHARMACEUTICALS PLCads	$0	–	-5,000	-100.0%	-0.33%	–
FATE	Exit	FATE THERAPEUTICS INC	$0	–	-59,600	-100.0%	-0.34%	–
STDY	Exit	STEADYMED LTD	$0	–	-215,214	-100.0%	-0.41%	–
CLSD	Exit	CLEARSIDE BIOMEDICAL INC	$0	–	-67,610	-100.0%	-0.43%	–
ACER	Exit	ACER THERAPEUTICS INC	$0	–	-41,795	-100.0%	-0.48%	–
ARRY	Exit	ARRAY BIOPHARMA INCcall	$0	–	-50,000	-100.0%	-0.48%	–
AIMT	Exit	AIMMUNE THERAPEUTICS INC	$0	–	-25,782	-100.0%	-0.48%	–
BHVN	Exit	BIOHAVEN PHARMACTL HLDG CO L	$0	–	-32,186	-100.0%	-0.49%	–
EXEL	Exit	EXELIXIS INC	$0	–	-40,000	-100.0%	-0.52%	–
EOLS	Exit	EVOLUS INC	$0	–	-102,544	-100.0%	-0.55%	–
KALA	Exit	KALA PHARMACEUTICALS INC	$0	–	-65,000	-100.0%	-0.61%	–
CFMS	Exit	CONFORMIS INC	$0	–	-731,041	-100.0%	-0.63%	–
INCY	Exit	INCYTE CORP	$0	–	-15,000	-100.0%	-0.74%	–
CSII	Exit	CARDIOVASCULAR SYS INC DEL	$0	–	-67,000	-100.0%	-0.87%	–
FOLD	Exit	AMICUS THERAPEUTICS INC	$0	–	-100,000	-100.0%	-0.89%	–
AGN	Exit	ALLERGAN PLCput	$0	–	-10,000	-100.0%	-0.99%	–
AMGN	Exit	AMGEN INCcall	$0	–	-10,000	-100.0%	-1.01%	–
NTUS	Exit	NATUS MED INC DEL	$0	–	-57,620	-100.0%	-1.14%	–
ARNA	Exit	ARENA PHARMACEUTICALS INC	$0	–	-50,000	-100.0%	-1.17%	–
RIGL	Exit	RIGEL PHARMACEUTICALS INCput	$0	–	-600,000	-100.0%	-1.26%	–
UTHR	Exit	UNITED THERAPEUTICS CORP DEL	$0	–	-20,000	-100.0%	-1.33%	–
QGEN	Exit	QIAGEN NV	$0	–	-75,000	-100.0%	-1.43%	–
ALXN	Exit	ALEXION PHARMACEUTICALS INCput	$0	–	-30,000	-100.0%	-1.98%	–
EW	Exit	EDWARDS LIFESCIENCES CORP	$0	–	-25,000	-100.0%	-2.06%	–
BMRN	Exit	BIOMARIN PHARMACEUTICAL INC	$0	–	-43,700	-100.0%	-2.09%	–
ABT	Exit	ABBOTT LABS	$0	–	-60,500	-100.0%	-2.14%	–
INCY	Exit	INCYTE CORPput	$0	–	-50,000	-100.0%	-2.46%	–
CI	Exit	CIGNA CORPORATIONcall	$0	–	-35,000	-100.0%	-3.47%	–
BMY	Exit	BRISTOL-MYERS SQUIBB COcall	$0	–	-100,000	-100.0%	-3.74%	–
MRK	Exit	MERCK & CO. INCcall	$0	–	-200,000	-100.0%	-6.44%	–

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR/A filed 2021-02-11

Signatures

The EDGAR filing(s) were signed by:

Alyssa Romano — Chief Compliance Officer and Chief Financial Officer

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
ICU MED INC	26	Q2 2023	4.2%
NANOSTRING TECHNOLOGIES INC	26	Q2 2023	3.3%
VIEWRAY INC	25	Q2 2023	3.2%
LIVANOVA PLC	23	Q3 2023	3.8%
ALEXION PHARMACEUTICALS INC	23	Q1 2021	4.3%
INSPIRE MED SYS INC	22	Q3 2023	3.7%
BOSTON SCIENTIFIC CORP	22	Q3 2022	4.8%
INVACARE CORP	22	Q3 2021	2.8%
ESTABLISHMENT LABS HLDGS INC	21	Q3 2023	5.0%
INTERSECT ENT INC	21	Q2 2021	2.6%

View PURA VIDA INVESTMENTS, LLC's complete holdings history.

Latest significant ownerships (13-D/G)

PURA VIDA INVESTMENTS, LLC Q2 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
Stryve Foods Holdings, LLC	April 19, 2023	1,470,649	5.6%
ICAD INC	March 15, 2023	1,277,214	5.0%
ESTABLISHMENT LABS HOLDINGS INC.	February 14, 2023	1,002,767	4.1%
Pulmonx Corp	February 14, 2023	1,216,258	3.2%
Quotient Ltd^{Sold out}	February 14, 2023	0	0.0%
Universe Pharmaceuticals INC^{Sold out}	February 14, 2023	0	0.0%
MedMen Enterprises, Inc.	April 29, 2022	139,755,072	21.4%
INVACARE CORP^{Sold out}	February 14, 2022	0	0.0%
MedAvail Holdings, Inc.	February 14, 2022	714,120	2.2%
TELA Bio, Inc.	February 14, 2022	564,120	3.9%

View PURA VIDA INVESTMENTS, LLC's complete significant-ownership history.

Latest filings

Type	Filed
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
13F-HR	2024-02-13
SC 13D/A	2023-12-29

View PURA VIDA INVESTMENTS, LLC's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

The reported total value is incorrect (249512000.0 != 249519000.0)
The reported has been restated
The reported has been amended

Export PURA VIDA INVESTMENTS, LLC's holdings